These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 38447169)
1. ACE mRNA (Additional Chimeric Element incorporated IVT mRNA) for Enhancing Protein Expression by Modulating Immunogenicity. Son S; Park M; Kim J; Lee K Adv Sci (Weinh); 2024 May; 11(18):e2307541. PubMed ID: 38447169 [TBL] [Abstract][Full Text] [Related]
2. N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products. Kim KQ; Burgute BD; Tzeng SC; Jing C; Jungers C; Zhang J; Yan LL; Vierstra RD; Djuranovic S; Evans BS; Zaher HS Cell Rep; 2022 Aug; 40(9):111300. PubMed ID: 35988540 [TBL] [Abstract][Full Text] [Related]
3. N Chen TH; Potapov V; Dai N; Ong JL; Roy B Sci Rep; 2022 Jul; 12(1):13017. PubMed ID: 35906281 [TBL] [Abstract][Full Text] [Related]
4. N Mokuda S; Watanabe H; Kohno H; Ishitoku M; Araki K; Hirata S; Sugiyama E Cytotechnology; 2022 Aug; 74(4):503-514. PubMed ID: 35791402 [TBL] [Abstract][Full Text] [Related]
5. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. Andries O; Mc Cafferty S; De Smedt SC; Weiss R; Sanders NN; Kitada T J Control Release; 2015 Nov; 217():337-44. PubMed ID: 26342664 [TBL] [Abstract][Full Text] [Related]
6. N Mulroney TE; Pöyry T; Yam-Puc JC; Rust M; Harvey RF; Kalmar L; Horner E; Booth L; Ferreira AP; Stoneley M; Sawarkar R; Mentzer AJ; Lilley KS; Smales CM; von der Haar T; Turtle L; Dunachie S; Klenerman P; Thaventhiran JED; Willis AE Nature; 2024 Jan; 625(7993):189-194. PubMed ID: 38057663 [TBL] [Abstract][Full Text] [Related]
7. In Vitro Transcribed mRNA Immunogenicity Induces Chemokine-Mediated Lymphocyte Recruitment and Can Be Gradually Tailored by Uridine Modification. Drzeniek NM; Kahwaji N; Picht S; Dimitriou IM; Schlickeiser S; Moradian H; Geissler S; Schmueck-Henneresse M; Gossen M; Volk HD Adv Sci (Weinh); 2024 Jun; 11(21):e2308447. PubMed ID: 38491873 [TBL] [Abstract][Full Text] [Related]
8. RNA sensor response in HeLa cells for transfected mRNAs prepared Nagaraj S; Stankiewicz-Drogon A; Darzynkiewicz E; Grzela R Front Bioeng Biotechnol; 2022; 10():1017934. PubMed ID: 36406230 [No Abstract] [Full Text] [Related]
10. Immuno-engineered mRNA combined with cell adhesive niche for synergistic modulation of the MSC secretome. Drzeniek NM; Kahwaji N; Schlickeiser S; Reinke P; Geißler S; Volk HD; Gossen M Biomaterials; 2023 Mar; 294():121971. PubMed ID: 36634491 [TBL] [Abstract][Full Text] [Related]
11. Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. Moradian H; Roch T; Anthofer L; Lendlein A; Gossen M Mol Ther Nucleic Acids; 2022 Mar; 27():854-869. PubMed ID: 35141046 [No Abstract] [Full Text] [Related]
12. Co-delivery of NS1 and BMP2 mRNAs to murine pluripotent stem cells leads to enhanced BMP-2 expression and osteogenic differentiation. Wang P; Logeart-Avramoglou D; Petite H; Goncalves C; Midoux P; Perche F; Pichon C Acta Biomater; 2020 May; 108():337-346. PubMed ID: 32251783 [TBL] [Abstract][Full Text] [Related]
13. An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. Nielsen JS; Wick DA; Tran E; Nelson BH; Webb JR J Immunol Methods; 2010 Aug; 360(1-2):149-56. PubMed ID: 20637775 [TBL] [Abstract][Full Text] [Related]
14. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Guan S; Rosenecker J Gene Ther; 2017 Mar; 24(3):133-143. PubMed ID: 28094775 [TBL] [Abstract][Full Text] [Related]
15. Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases. Vadovics M; Muramatsu H; Sárközy A; Pardi N Methods Mol Biol; 2024; 2786():167-181. PubMed ID: 38814394 [TBL] [Abstract][Full Text] [Related]
16. RNA ImmunoGenic Assay: A Method to Detect Immunogenicity of Haque AA; Weinmann P; Biswas S; Handgretinger R; Mezger M; Kormann MSD; Antony JS Bio Protoc; 2020 Dec; 10(24):e3850. PubMed ID: 33855105 [TBL] [Abstract][Full Text] [Related]
17. Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics. Kang DD; Li H; Dong Y Adv Drug Deliv Rev; 2023 Aug; 199():114961. PubMed ID: 37321375 [TBL] [Abstract][Full Text] [Related]
18. A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA. Baiersdörfer M; Boros G; Muramatsu H; Mahiny A; Vlatkovic I; Sahin U; Karikó K Mol Ther Nucleic Acids; 2019 Apr; 15():26-35. PubMed ID: 30933724 [TBL] [Abstract][Full Text] [Related]
19. News from Mars: Two-Tier Paradox, Intracellular PCR, Chimeric Junction Shift, Dark Matter mRNA and Other Remarkable Features of Mammalian RNA-Dependent mRNA Amplification. Implications for Alzheimer's Disease, RNA-Based Vaccines and mRNA Therapeutics. Volloch V; Rits-Volloch S Ann Integr Mol Med; 2021; 2():131-173. PubMed ID: 33942036 [TBL] [Abstract][Full Text] [Related]
20. IVT-mRNA reprogramming of myeloid cells for cancer immunotherapy. Jolly KJ; Zhang F Adv Pharmacol; 2024; 100():247-288. PubMed ID: 39034054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]